Summary
- Profile Type
- Business Offer
- POD Reference
- BOCY20250218006
- Term of Validity
- 24 March 2025 - 24 March 2026
- Company's Country
- Cyprus
- Type of partnership
- Investment agreement
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Cyprus based biomedical engineering company has developed a cutting-edge laboratory automation system designed to streamline molecular diagnostic workflows and facilitate CE-IVDR certification. The company is looking for potential distributors.
- Full Description
-
The Cypriot company was established in 2018 by a team of highly skilled and passionate experts, focusing on developing high-quality technological solutions for the global healthcare market.
In 2020, the company was awarded the Certificate of Innovative SME by the Deputy Ministry of Research, Innovation, and Digital Policy.
Since its establishment, the company has successfully secured multiple competitive funding grants from the Research and Innovation Foundation of Cyprus and the Cypriot Ministry of Industry and Commerce (Young Entrepreneurship Award), totaling €780,000.
The company has already designed a state-of-the-art prototype automation platform—an adjustable robotic system that can automate a wide range of laboratory procedures. This innovative platform addresses bottlenecks in everyday research workflows, reduces human error, and increases overall productivity. The system serves as a pre-diagnostic processing tool, facilitating routine laboratory tasks and accelerating workflows. It is capable of automating microbiological procedures, genetic testing, and molecular diagnostics for the detection, identification, and quantification of multiple microbes and pathogens, using a species-agnostic approach, ensuring CE-IVDR compliance.
Unlike other robotic systems on the market, which are designed to repeat the same procedure for multiple samples, this platform is uniquely built to perform multiple procedures for a limited number of samples. Its versatility makes it the only system capable of handling everyday laboratory tasks, where human handling inconsistencies are a common issue.
By eliminating these inconsistencies, the company aims to address the reproducibility crisis—a significant problem where 70% of published scientific data is non-reproducible and, therefore, unreliable, resulting in an estimated $28 billion USD in annual losses. Through its innovative solutions, the company aspires to enhance research reliability and improve scientific outcomes globally.
It is worth noted that the company has now a partnership with one of the Top World Universities and other distinguished institutions. - Advantages and Innovations
-
Products & Services
AMGEL4TT– Lab Automation
A robotic workstation for DNA/RNA extraction, PCR, and diagnostics, offering:
AI-driven automation for accuracy and reproducibility
Compact, cost-effective design (30% cheaper than competitors)
Open-system compatibility with existing lab equipment
AMGEL4TT – Research to Market
Tailored for molecular diagnostics, ensuring:
Seamless research-to-clinic transition with CE-IVDR compliance
Customizable workflows without coding
Built-in quality control for accuracy
Leasing & Custom Automation
Affordable leasing models for easy adoption
Custom automation solutions for specialized lab needs
Why Partner with the CY company?
1. Accelerated Market Entry for Molecular Diagnostics
AMGEL4TT streamlines the path from R&D to clinical application, supporting CE-IVDR certification for diagnostic technologies.
Ensures regulatory compliance and quality control, reducing time-to-market for lab-developed tests (LDTs).
2. AI-Driven Automation for Higher Reproducibility
Eliminates human error and increases result consistency by 90%, making molecular assays more reliable.
Real-time error detection and workflow optimization, ensuring every step meets precision standards.
3. Open-Platform Flexibility & Customization
Unlike closed-system competitors (Hamilton, Agilent), AMGEL integrates with any lab equipment.
Modular design supports multiple diagnostic protocols, including PCR, qPCR, NGS sample prep, and multiplex assays.
4. Cost-Effective Scaling for Diagnostic Labs
30% more affordable than high-end automation brands.
Leasing model allows partners to scale without high upfront investment, ensuring faster adoption.
5. Sustainability & Efficiency
Reduces consumable waste by 70% and lowers energy consumption by 50%, improving lab sustainability.
Automates sample prep, reducing manual workload and freeing up skilled personnel for high-value tasks. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 12: Responsible Consumption and Production
- IPR status
- IPR granted
- IPR notes
- Utility patent in 26 EU countries
Partner Sought
- Expected Role of a Partner
-
They are looking for partners with expertise in:
Clinical diagnostics distribution (laboratory automation, molecular testing, and biotech solutions)
Scaling molecular diagnostic products from R&D to commercial deployment
Healthcare & laboratory market access (hospitals, research labs, reference laboratories)
Tasks and Responsibilities
1. Market Access & Distribution
Leverage established distribution networks to introduce AMGEL4TT into diagnostic labs, biotech firms, and healthcare institutions.
Identify key markets and sales channels for AMGEL4TT, focusing on Europe, the UK, and the U.S..
Facilitate partnerships with reference labs, contract research organizations (CROs), and biotech companies.
2. Scaling Molecular Diagnostic Products
Support the transition of AMGEL4TT from a research tool to a widely adopted clinical diagnostics platform.
Develop localized go-to-market strategies for hospitals, academic research centers, and molecular testing providers.
Provide customer onboarding, training, and support for lab automation adoption.
3. Hospital & Healthcare Sector Engagement
Establish connections with hospitals, diagnostic service providers, and national healthcare systems to integrate AMGEL4TT into clinical workflows.
Engage with molecular pathology labs and oncology testing centers to demonstrate AMGEL4TT’s impact on reproducibility and efficiency.
Support regulatory positioning and CE-IVDR adoption to ensure AMGEL4TT meets compliance standards in clinical settings.
Strategic Benefits of Partnership
Faster market penetration through established networks.
Increased adoption of automated molecular diagnostics, reducing human error and turnaround time.
Recurring revenue streams through AMGEL4TT’s leasing-based business model.
Exclusive early access to a patented, AI-driven lab automation technology with high market potential.
We seek partners with a proven track record in commercializing molecular diagnostics solutions and the ability to scale AMGEL4TT adoption across hospitals, research centers, and biotech labs. If your company specializes in market access, distribution, and commercialization in clinical diagnostics, we invite you to collaborate. - Type and Size of Partner
- SME <=10
- Other
- SME 50 - 249
- R&D Institution
- Big company
- University
- SME 11-49
- Type of partnership
- Investment agreement
- Commercial agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06001013 - Medical Technology / Biomedical Engineering
- Market keywords
- 05004003 - Laboratory equipment
- 05001002 - In-vitro diagnostics
- 05001005 - Molecular diagnosis
- Targeted countries
- All countries